Cipher Pharmaceuticals Inc. CPH
TSX · Canada · Health Technology
CAD 13.650.00 (0.00%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") is pleased to announce the appointment of Rajiv De Silva to the Company's Board of Directors (the "Board"), effective today, September 21, 2026.
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") has received a favourable decision from the New York federal court (the "Court") regarding the petition filed by Sun Pharmaceutical Industries, Inc. ("Sun") in October 2025, seeking to partially vacate the portions of an arbitrator's award that affirmed Cipher's ownership of the clinical data involved in Sun's launch of Absorica LD® in Canada and granted remedies in Cipher's favour (the "Arbitration Award").
Despite a 10% revenue dip from Medicaid-related Natroba declines, Cipher boosts Epuris market share to 47.1% and secures a major Walmart retail partnership.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.